Holiday Notice: Expect delayed shipping. Orders ship 4/6.
FOR RESEARCH PURPOSES ONLY. NOT FOR HUMAN CONSUMPTION.

CJC-1295 + Ipamorelin — Published Research

Reviewed by: Dr. James Porter, PhD| Last updated: February 24, 2026|For laboratory reference only

← Back to CJC-1295 + Ipamorelin product page

Research Library

Published research on these compounds — for educational purposes only

GHRH and GHS Receptor Synergistic Signaling

The combination of GHRH analogs with growth hormone secretagogues (GHS) has been investigated for synergistic effects on somatotroph cells. GHRH activates the GHRH receptor (a class B GPCR) through cAMP/PKA signaling, while GHS peptides like ipamorelin activate the GHS-R1a receptor through phospholipase C/IP3/calcium pathways. Co-stimulation of both receptor systems on the same pituitary cell produces GH release that exceeds the sum of individual stimulations, as characterized in perfused rat pituitary models.

Bowers CY et al. “On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.” Endocrinology. 1984. PubMed

Ipamorelin Selectivity Profile

Ipamorelin (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) is a pentapeptide GH secretagogue characterized by high selectivity for GH release relative to other pituitary hormones. In swine pituitary cell culture models, ipamorelin stimulated GH release with an EC₅₀ of approximately 1.3 nM without significant effects on ACTH, cortisol, prolactin, or FSH/LH release at effective concentrations. This selectivity profile distinguishes it from earlier GHS compounds like GHRP-6 and hexarelin, which show broader hormonal stimulation.

Raun K et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998. PubMed

CJC-1295 (Mod GRF 1-29) Structure and Pharmacokinetics

CJC-1295 without DAC (also known as Modified GRF 1-29) is a tetra-substituted analog of GHRH(1-29) with modifications at positions 2 (D-Ala), 8 (Gln), 15 (Ala), and 27 (Leu). These substitutions confer resistance to DPP-IV and other proteolytic enzymes, extending the biological half-life from the approximately 7-minute native GHRH half-life to roughly 30 minutes. The peptide retains full agonist activity at the GHRH receptor with equivalent binding affinity to native GHRH(1-29).

Ionescu M, Frohman LA. “Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.” J Clin Endocrinol Metab. 2006. PubMed

Disclaimer: All research citations are provided for educational purposes only. These references describe findings from in vitro and animal model studies. This information does not constitute medical advice and should not be interpreted as endorsement of any specific application.

Reviewed by

Dr. James Porter, PhD

Biochemist with a focus on peptide synthesis and structure-activity relationships. Reviews research summaries for scientific accuracy.

Editorial Review

Reviewed by Dr. Sarah Chen, PharmD and Dr. James Porter, PhD — Panda Peptides Research Team.

Last reviewed: April 2026.

This content summarizes published peer-reviewed research for educational purposes only. It is not medical advice and does not constitute a recommendation for any specific compound or protocol.